2,3-dichloro-7-cyano-4-hydroxy-1-(4-methoxy-benzyl)-1H-pyrrolo[2,3-c]pyridine-5-carboxylic acid ethyl ester | 952397-51-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 2,3-dichloro-7-cyano-4-hydroxy-1-(4-methoxy-benzyl)-1H-pyrrolo[2,3-c]pyridine-5-carboxylic acid ethyl ester
• 英文别名: ethyl 2,3-dichloro-7-cyano-4-hydroxy-1-[(4-methoxyphenyl)methyl]pyrrolo[2,3-c]pyridine-5-carboxylate
• CAS: 952397-51-2
• 化学式: C₁₉H₁₅Cl₂N₃O₄
• 分子量: 420.252
• InChiKey: VHGZVRVLSWKNEK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  97.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2,3-dichloro-7-cyano-4-hydroxy-1-(4-methoxy-benzyl)-1H-pyrrolo[2,3-c]pyridine-5-carboxylic acid ethyl ester 、 聚甘氨酸 、 sodium methoxide methanol 生成 {[2,3-dichloro-7-cyano-4-hydroxy-1-(4-methoxy-benzyl)-1H-pyrrolo[2,3-c]pyridine-5-carbonyl]-amino}-acetic acid
  参考文献：
  名称：

  Pyrrolo- and Thiazolo-pyridine compounds, and methods of use thereof

  摘要：

  本发明涉及能够调节缺氧诱导因子（HIF）稳定性和/或活性的新化合物。

  公开号：

  US07696223B2
• 作为产物：
  描述：

  7-cyano-4-hydroxy-1-(4-methoxy-benzyl)-1H-pyrrolo[2,3-c]pyridine-5-carboxylic acid ethyl ester 在 N-氯代丁二酰亚胺 作用下， 以 乙腈 为溶剂， 反应 1.0h， 生成 2,3-dichloro-7-cyano-4-hydroxy-1-(4-methoxy-benzyl)-1H-pyrrolo[2,3-c]pyridine-5-carboxylic acid ethyl ester
  参考文献：
  名称：

  PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF

  摘要：

  这项发明涉及一种能够调节缺氧诱导因子（HIF）稳定性和/或活性的新化合物。

  公开号：

  US20080004309A1

文献信息

• Novel benzimidazole derivatives
  申请人：Otake Norikazu

  公开号：US20060205750A1

  公开（公告）日：2006-09-14

  The present invention relates to a compound of the formula (I): (wherein A, B , C and D are independently nitrogen or optionally substituted methine; E is nitrogen, methine or hydroxy substituted methine; n is 0 or 1; T, U, V and W are independently nitrogen or optionally substituted methine; X is —N(SO 2 R 4 )—, —N(COR 5 )— or —CO—; Y is —C(R 6 )(R 7 )—, —O— or —N(R 8 )—, provided that the compound (I) when E is nitrogen, n is 0, X is —CO—, and Y is —O— is excluded) and the like, which are useful as an agent for the treatment of various diseases related to NPY, for example cardiovascular disorders such as angina, acute or congestive heart failure, myocardial infarction, hypertension, nephropathy, electrolyte abnormality, vasospasm, arteriosclerosis, etc., central nervous system disorders such as bulimia, depression, anxiety, seizure, epilepsy, dementia, pain, alcoholism, drug withdrawal, circadian rhythm disorders, schizophrenia, memory impairment, sleep disorders, cognitive impairment, etc., metabolic diseases such as obesity, diabetes, hormone abnormality, hypercholesterolemia, hyperlipidemia, gout, fatty liver, etc., genital or reproductive disorders such as infertility, preterm labor, sexual dysfunction, etc., gastro-intestinal disorders, respiratory disorder, inflammatory diseases or glaucoma, and the like, also for example, atherosclerosis, hypogonadism, hyperandrogenism, polycystic ovary syndrome (Pickwickian syndrome), hirsutism, gastro-intestinal motility disorder, obesity-related gastro-esophageal reflux, obesity hypoventilation, sleep apnea, inflammation, systemic inflammation of the vasculature, osteoarthritis, insulin resistance, bronchoconstriction, alcohol preference, metabolic syndrome, Alzheimer's disease, cardiac hypertrophy, left ventricular hypertrophy, hypertriglyceridemia, low HDL cholesterol, cardiovascular disorders such as coronary heart disease (CHD), cerebrovascular disease, stroke, peripheral vascular disease, sudden death, gallbladder diseases, cancer (breast, endometrial, colon), breathlessness, hyperuricemia, impaired fertility, low back pain, or increased anesthetic risk, and the like.

  本发明涉及一种式(I)的化合物：其中A、B、C和D分别独立表示氮或可选取代的甲烷基；E表示氮、甲烷基或羟基取代的甲烷基；n为0或1；T、U、V和W分别独立表示氮或可选取代的甲烷基；X为—N（SO2R4）—、—N（COR5）—或—CO—；Y为—C（R6）（R7）—、—O—或—N（R8）—，但当化合物（I）中E为氮，n为0，X为—CO—，Y为—O—时，该化合物被排除在外。此外，该化合物及其类似物可用作治疗与NPY相关的各种疾病的药物，例如心血管疾病如心绞痛、急性或充血性心力衰竭、心肌梗死、高血压、肾病、电解质异常、血管痉挛、动脉硬化等；中枢神经系统疾病如贪食症、抑郁症、焦虑症、癫痫、痴呆、疼痛、酗酒、戒断症状、生物钟紊乱、精神分裂症、记忆力减退、睡眠障碍、认知障碍等；代谢性疾病如肥胖症、糖尿病、激素异常、高胆固醇血症、高脂血症、痛风、脂肪肝等；生殖系统疾病如不孕症、早产、性功能障碍等；胃肠道疾病、呼吸系统疾病、炎症性疾病或青光眼等；例如动脉粥样硬化、性腺功能减退、高雄激素血症、多囊卵巢综合症（皮克威克综合症）、多毛症、胃肠道运动障碍、肥胖相关的胃食管反流、肥胖低通气综合症、睡眠呼吸暂停、炎症、血管系统全身性炎症、骨关节炎、胰岛素抵抗、支气管收缩、酒精偏好、代谢综合症、阿尔茨海默病、心脏肥大、左心室肥大、高三酰甘油血症、低高密度脂蛋白胆固醇、心血管疾病如冠心病、脑血管疾病、中风、周围血管疾病、猝死、胆囊疾病、癌症（乳腺、子宫内膜、结肠）、呼吸困难、高尿酸血症、生育能力下降、腰痛或麻醉风险增加等。
• THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS
  申请人：Fibrogen, Inc.

  公开号：EP3124489A1

  公开（公告）日：2017-02-01

  The present invention relates to novel compounds of formula I wherein: q is 0 or 1; • A is -S- and B is =N-; or • A is =N- and B is -S-; one of -A≃C(R6)- or -B≃C(R6)- is a double bond and the other is a single bond; R1 is selected from the group consisting of hydroxyl, alkoxy, substituted alkoxy, acyloxy, cycloalkoxy, substituted cycloalkoxy, aryloxy, substituted aryloxy, heteroaryloxy, substituted heteroaryloxy, heterocyclyloxy, substituted heterocyclyloxy, mercapto, thioether, sustituted alkylthio, arylsulfanyl, heteroarylsulfanyl, amino, substituted amino, acylamino, and aminoacyl; R2is selected from the group consisting of hydrogen, deuterium, and methyl; R3 is selected from the group consisting of hydrogen, deuterium, alkyl, and substituted alkyl; R4 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl; and R5 and R6 are as defined in claim 1; capable of modulating the stability and/or activity of hypoxia inducible factor (HIF).

  本发明涉及式 I 的新型化合物 其中 q 是 0 或 1； - A 是-S-，B 是＝N-；或 - A 是 =N-，B 是 -S-； -A≃C(R6)-或-B≃C(R6)-中的一个是双键，另一个是单键； R1 选自由羟基、烷氧基、取代的烷氧基、酰氧基、环烷氧基、取代的环烷氧基、芳氧基、取代的芳氧基、杂芳氧基、取代的杂芳氧基、杂环氧基、取代的杂环氧基、巯基、硫醚、取代的烷硫基、芳硫基、杂芳硫基、氨基、取代的氨基、酰氨基和氨基酰基组成的组； R2 选自氢、氘和甲基组成的组； R3 选自氢、氘、烷基和取代烷基组成的组； R4 选自由氢、烷基和取代烷基组成的组；以及 R5 和 R6 如权利要求 1 所定义； 能调节缺氧诱导因子（HIF）的稳定性和/或活性。
• EP2016078B1
  申请人：——

  公开号：EP2016078B1

  公开（公告）日：2016-06-15
• PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS
  申请人：FIBROGEN, INC.

  公开号：EP2016078A2

  公开（公告）日：2009-01-21
• US7687514B2
  申请人：——

  公开号：US7687514B2

  公开（公告）日：2010-03-30